Indinavir

Generic name
Indinavir
Brand name
ATC Code
J05AE02
Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

No information

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Treatment HIV infection
  • Oral
    • 1 month up to 18 years
      • 1.800 mg/m²/day in 3 doses. Max: 2.400 mg/day. Max single dose: 800 mg/dose.
      • Directions for administration:

        Take on an empty stomach

      • Prescribing antiretroviral therapy for children is an action that is reserved for the doctors in HIV teams. The available combinations in retroviral therapy are continually changing. The above-mentioned dosing is therefore only a guide.
HIV, treatment in combination with ritonavir
  • Oral
    • 1 month up to 18 years
      • 800 mg/m²/day in 2 doses.
      • Directions for administration:

        Take on an empty stomach

      • Ritonavir:  250 mg/m²/day in 2 doses

        Prescribing antiretroviral therapy for children is an action that is reserved for the doctors in HIV teams. The available combinations in retroviral therapy are continually changing. The above-mentioned dosing is therefore only a guide.

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

In clinical research in children (≥ 3 years), the side effect profile was in general the same as that for adult patients with the exception of a higher frequency of nephrolithiasis, at 29% (20 out of 70) in children. Asymptomatic pyuria of unknown aetiology was noticed in 10.9% (6 out of 55) of the children. Some of these cases involved mild elevation of the serum creatinine.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

Given the risk of nephrolithiasis, it is recommended that at least 1½ litre should be drunk daily, or for children of < 20 kg at least 75 ml/kg bodyweight per day and for children of 20-40 kg at least 50 ml/kg bodyweight per day.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

DIRECT ACTING ANTIVIRALS

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Nucleosides and nucleotides excl. reverse transcriptase inhibitors
J05AB01
J05AB12
J05AB06
J05AB16
J05AB04
J05AB11
J05AB14
Phosphonic acid derivatives
J05AD01
Protease inhibitors
J05AE08
J05AE10
J05AE07
J05AE04
J05AE03
J05AE01
Nucleoside and nucleotide reverse transcriptase inhibitors
J05AF06
J05AF02
J05AF09
J05AF10
J05AF05
J05AF04
J05AF07
J05AF13
J05AF13
J05AF01
Non-nucleoside reverse transcriptase inhibitors
J05AG06
J05AG03
J05AG04
J05AG01
J05AG05
Neuraminidase inhibitors
J05AH02
J05AH01
Antivirals for treatment of HIV infections, combinations
J05AR02
J05AR20
J05AR13
J05AR25
J05AR18
J05AR19
J05AR03
J05AR09
J05AR10
Other antivirals
J05AX28
J05AX12
J05AX07
J05AX09
J05AX08
J05AX24
ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS
J05AR02
J05AR20
J05AR13
J05AR25
J05AR18
J05AR19
J05AR03
J05AR09
J05AR10
Integrase inhibitors
J05AJ04
Antivirals for treatment of HCV infections
J05AP54
J05AP57
J05AP51
J05AP08
J05AP55

References

  1. CBO, Richtlijn antiretrovirale therapie, www.cbo.nl, herziene versie december 2007
  2. Bamford, A., et al (PENTA Steering Committee) (2015), Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life., HIV Med., doi:10.1111
  3. Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children., Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection., Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf., Geraadpleegd 12 sept 2016

Changes

Therapeutic Drug Monitoring


Overdose